Evidence map›Paper›PMID 41084516›Full record

ArticleJournal of diabetes and metabolic disorders2025

Continuous subcutaneous octreotide infusion in congenital hyperinsulinism: practical application and insights in infancy and early childhood.

Mercedes J Burnside, Adam Stafford-Bell, Rachel Romans, Matthew Moller, Catherine S Choong, Mary B Abraham

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mercedes J BurnsideDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Perth, WA Australia.ORCID 0000-0002-8414-4479
Adam Stafford-BellMedical School, The University of Western Australia, Perth, WA Australia.
Rachel RomansDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Perth, WA Australia.
Matthew MollerDepartment of Pharmacy, Perth Children's Hospital, Perth, WA Australia.
Catherine S ChoongDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Perth, WA Australia.
Mary B AbrahamDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Perth, WA Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Octreotide is second-line treatment for patients with congenital hyperinsulinism (CHI) unresponsive to diazoxide. Short-acting octreotide is administered via subcutaneous (SC) injection or continuous infusion using a pump, but limited data exist on pump therapy. We present two cases of CHI managed with an octreotide infusion via pump with or without concurrent continuous glucose monitoring (CGM), providing practical guidance. Case presentation: Octreotide 500mcg/1ml ampoule was used. The starting dose was 5mcg/kg/day, with titration to optimize glycaemia, and delivered as a continuous basal rate using a pump. CGM was used by Patient 2.Patient 1: CHI due to a paternal Conclusion: This report highlights the practical use of octreotide infusion via pump. When combined with CGM, it allows for tailored dosing to meet individual needs while enhancing patient convenience.

Indexed as

Congenital hyperinsulinismContinuous infusionOctreotidePump

Identifiers

PMID41084516
PMCPMC12515156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.